Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Clinical Pharmacology in Drug Development|August 23, 2016
Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy SubjectsPeter N Morcos, Elena Guerini, Neil Parrott, et al.
Clinical Pharmacology in Drug Development|August 23, 2016
Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor AlectinibPeter N Morcos, Yumi Cleary, Elena Guerini, et al.
Clinical Pharmacology in Drug Development|August 23, 2016
Effect of the Wetting Agent Sodium Lauryl Sulfate on the Pharmacokinetics of Alectinib: Results From a Bioequivalence Study in Healthy SubjectsPeter N Morcos, Neil Parrott, Ludger Banken, et al.
Journal of Pharmaceutical Sciences|April 4, 2021
Managing the Impact of Immunogenicity in an Era of Immunotherapy: From Bench to BedsideKatharine Bray-French, Katharina Hartman, Guido Steiner, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 8, 2012
Glycine transporter type 1 occupancy by bitopertin: a positron emission tomography study in healthy volunteersMeret Martin-Facklam, Flavia Pizzagalli, Yun Zhou, et al.
Neuroimage|December 14, 2011
Characterization of [11C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humansDean F Wong, Susanne Ostrowitzki, Yun Zhou, et al.
JAMA Psychiatry|April 4, 2014
Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept studyDaniel Umbricht, Daniela Alberati, Meret Martin-Facklam, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|May 17, 2016
Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjectsPeter N Morcos, Li Yu, Katrijn Bogman, et al.
Frontiers in Immunology|June 17, 2024
Characterization of anti-drug antibody responses to the T-cell engaging bispecific antibody cibisatamab to understand the impact on exposureGregor P Lotz, Achim Lutz, Meret Martin-Facklam, et al.
JAMA Neurology|June 19, 2018
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical TrialJoseph Jankovic, Ira Goodman, Beth Safirstein, et al.
Pageof 4